As the NU-SL40 combination treatment regimen was intended to activate tumor-reactive T cells, we validated the role of CD8+ T cells and found that CD8+ T cell depletion ablated the antitumor activity of NU-SL40 therapy and reduced survival to that of untreated mice (Figure 1, B and C). The gene discussed is CD8A; the disease is neoplasm.